Evidence map›Paper›PMID 41819830›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Prognostic Value of Cycle 1 SPECT SUV

Alireza Ghodsi, Ridvan A Demirci, Roman Gulati, Peter S Nelson, Ruben Raychaudhuri, Heather H Cheng, Rajitha Sunkara, Hiba Khan, Rosa Nadal Rios, Andrew Hsieh and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. FDG/PSMA discordance in [Frontiers in oncology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alireza GhodsiDepartment of Radiology, University of Washington, Seattle, Washington.
Ridvan A DemirciDepartment of Radiology, University of Washington, Seattle, Washington.
Roman GulatiPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Peter S NelsonDepartment of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.
Ruben RaychaudhuriDepartment of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.
Heather H ChengDepartment of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.
Rajitha SunkaraDepartment of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.
Hiba KhanDepartment of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.
Rosa Nadal RiosDepartment of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.
Andrew HsiehDepartment of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.
Petros GrivasDepartment of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.
Bruce MontgomeryDepartment of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.
Todd A YezefskiDepartment of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.
Evan Y YuDepartment of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.
Michael T SchweizerDepartment of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington; and.
Delphine L ChenDepartment of Radiology, University of Washington, Seattle, Washington.
Amir IravaniDepartment of Radiology, University of Washington, Seattle, Washington; airavani@uw.edu.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
Modeling and analytics for cancer diagnostics: traversing the data-evidence divideR35CA274442 · NCI · FRED HUTCHINSON CANCER CENTER · PI RUTH D ETZIONI · 2022 to 2026
$4.9M
Statistical modeling to support population and translational cancer researchR50CA221836 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Roman Gulati · 2017 to 2026
$2.0M
NCI NIH HHS P30 CA015704NCI NIH HHS P50 CA097186NCI NIH HHS R35 CA274442NCI NIH HHS R50 CA221836
6 · The paper itself

Abstract

This study aimed to determine whether SPECT SUV

Indexed as

DipeptidesHeterocyclic CompoundsHeterocyclic Compounds, 1-RingProstatic Neoplasms, Castration-ResistantTomography, Emission-Computed, Single-PhotonAgedAged, 80 and overHumansLutetiumMaleMiddle AgedNeoplasm MetastasisPrognosisProstate-Specific AntigenRadioisotopesRadiopharmaceuticalsDipeptidesHeterocyclic CompoundsHeterocyclic Compounds, 1-RingLutetiumLutetium-177lutetium (177Lu) vipivotide tetraxetanProstate-Specific AntigenPSMA-617RadioisotopesRadiopharmaceuticals177Lu-PSMAmCRPCprostate cancerPSMA PET/CTSPECTSUVmean

Identifiers

PMID41819830
PMCPMC13224911

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.